- CG Oncology has **completed enrollment** in its Phase 3, randomized, open-label PIVOT-006 study.  **[1789972_e52eaaa6c2c24e60a0b4895ac74417f5_0]** 
- The PIVOT-006 study evaluates **cretostimogene grenadenorepvec** against surveillance for patients with **intermediate-risk non-muscle invasive bladder cancer (IR NMIBC)**.  **[1789972_e52eaaa6c2c24e60a0b4895ac74417f5_0]** 
- Enrollment was completed **nearly a year ahead of schedule**, highlighting the significant unmet need for new treatment options in this patient population, where no U.S. FDA-approved options currently exist.  **[1789972_e52eaaa6c2c24e60a0b4895ac74417f5_0]** 
- Cretostimogene is an **investigational oncolytic immunotherapy** being developed as a potential bladder-sparing therapeutic for bladder cancer.  **[1789972_e52eaaa6c2c24e60a0b4895ac74417f5_1]**

Cullinan Therapeutics (CGEM)